Publication | Closed Access
Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers.
104
Citations
0
References
1999
Year
Substance UseCannabinoid PharmacologyMolecular PharmacologyCannabinoid Antagonist Sr141716aAddiction MedicineDependence StatusEthanol-vapor ChambersHealth SciencesCannabis UsePsychiatryBehavioural PharmacologyBehavioral PharmacologyNeuropharmacologyAlcohol AbuseAlcohol-related Liver DiseasePharmacologyAlcohol DependenceCannabisSubstance AbuseAddictionPhysiologyMedicineEthanol Self-administration
To study the potential role of dependence status on CB1-mediated blockade of ethanol self-administration.We examined the effects of the cannabinoid antagonist SR141716A (0, 0.03, 0.3, and 3 mg/kg) on operant ethanol (10% v/v) self-administration in male Wistar rats that were made ethanol-dependent by chronic (14 d) exposure to ethanol vapor-chambers or exposed to air in identical vapor chambers.Dependent animals responded more for ethanol than did air control nondependent rats. The acute administration of a 3 mg/kg dose of SR141716A almost suppressed ethanol self-administration only in ethanol dependent animals. However, operant responses for food were not affected by the administration of SR141716A.These results further support that cannabinoid CB1 receptor blockade may have a potential utility for the treatment of alcoholism.